Advertisement

Drugs

, Volume 79, Issue 1, pp 99–103 | Cite as

Emapalumab: First Global Approval

  • Zaina T. Al-SalamaEmail author
AdisInsight Report

Abstract

Emapalumab-Izsg (hereafter referred to as emapalumab) [Gamifant®] is a monoclonal antibody directed against interferon gamma that is available as an intravenous infusion. Emapalumab is being developed by Novimmune and Swedish Orphan Biovitrum for the treatment of haemophagocytic lymphohistiocytosis (HLH). In November 2018, emapalumab received its first global approval in the USA, for the treatment of paediatric (newborn and older) and adult patients with primary HLH, who have refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. Emapalumab is under regulatory review in the EU for the treatment of primary HLH. This article summarizes the milestones in the development of emapalumab leading to this first global approval for HLH in the USA.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Zaina T. Al-Salama is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Daver N, McClain K, Allen CE, et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017;123(17):3229–40.CrossRefGoogle Scholar
  2. 2.
    UK National Institute for Health Research. Emapalumab for primary haemophagocytic lymphohistiocytosis. 2018. http://www.io.nihr.ac.uk/. Accessed 7 Dec 2018.
  3. 3.
    De Min C, Buatois V, Chatel L, et al. Interferon gamma (IFNg) is the driving mediator of secondary hemophagocytic lymphohistiocytosis (sHLH) in TLR9-mediated pathogenesis in mice and is correlated to disease parameters in children [abstract no. 3076]. Arthritis Rheumatol. 2015;67(Suppl. 10):3691–2.Google Scholar
  4. 4.
    Prencipe G, Caiello I, Pascarella A, et al. Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2018;141(4):1439–49.CrossRefGoogle Scholar
  5. 5.
    Jordan MB, Hildeman D, Kappler J, et al. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735–43.CrossRefGoogle Scholar
  6. 6.
    Pachlopnik Schmid J, Ho CH, Chrétien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med. 2009;1(2):112–24.CrossRefGoogle Scholar
  7. 7.
    Novimmune SA. GAMIFANTTM (emapalumab-lzsg): prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107lbl.pdf. Accessed 7 Dec 2018.
  8. 8.
    US Food and Drug Administration (FDA). FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease [media release]. 2018. https://www.fda.gov/NewsEvents/. Accessed 7 Dec 2018.
  9. 9.
    Swedish Orphan Biovitrum. SobiTM completes acquisition of the global rights for emapalumab from Novimmune [media release]. 2018. http://www.sobi.com. Accessed 7 Dec 2018.
  10. 10.
    Swedish Orphan Biovitrum. SobiTM strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune [media release]. 2018. http://www.sobi.com. Accessed 7 Dec 2018.
  11. 11.
    Jordan M, Locatelli F, Allen C, et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNgamma) monoclonal antibody (MAB), NI-0501: first results from a pilot phase 2 study in children with primary HLH [abstract plus presentation]. Blood. 2015;126(23):LBA-3.Google Scholar
  12. 12.
    Hatterer E, Richard F, Malinge P, et al. Investigating the novel mechanism of action for NI-0501, a human interferon gamma monoclonal antibody [abstract no. P156]. Cytokine. 2012;59(3):570.CrossRefGoogle Scholar
  13. 13.
    Locatelli F, Jordan M, Allen C, et al. Anti-interferon gamma monoclonal antibody NI-0501: a new option to render allogeneic HSCT for HLH safer and more effective? [abstract no. O147]. Bone Marrow Transplant. 2016;51(Suppl):S86.Google Scholar
  14. 14.
    Jordan MB, Locatelli F, Allen C, et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with NI-0501, an anti-interferon gamma monoclonal antibody [abstract no. 4511]. J Clin Immunol. 2016;36(3):282.Google Scholar
  15. 15.
    Locatelli F, Jordan MB, Allen CE, et al. Safety and efficacy of emapalumab in pediatric patients with primary hemophagocytic lymphohistiocytosis [abstract no. LBA-6]. In: The American Society of Hematology Annual Meeting. 2018.Google Scholar
  16. 16.
    De Min C, Jacqmin P, Laveille C, et al. Innovative approach for the identification of an appropriate dose regimen of a targeted treatment, NI-0501, an anti-interferon gamma (IFNg) antibody, in patients with hemophagocytic lymphohistiocytosis (HLH) [abstract no. 3097]. Arthritis Rheumatol. 2015;67(Suppl. 10):3712.Google Scholar
  17. 17.
    Locatelli F, Jordan M, Allen C, et al. Interferon gamma (IFN-gamma) neutralization as a valuable therapeutic target in primary HLH [abstract no. P343]. Haematologica. 2016;101(Suppl. 1):114–5.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations